Somatostatin Prevent Post-operation Pancreatic Fistula in Intermediate Risk Patients After Pancreaticoduodenectomy
Status:
Completed
Trial end date:
2019-05-24
Target enrollment:
Participant gender:
Summary
This study is designed to assess the preventive effects of somatostatin on post-operation
pancreatic fistula in intermediate risk patients after pancreaticoduodenectomy. Patients
assigned into the treatment group will be continuous intravenous infusion with the
somatostatin (Stilamin®) in addition to conventional treatments (including infection
prevention, nutrition support and acid suppression therapy, etc.).The pancreatic fistula
incidence will be monitored within 30 days after operation.